Cargando…

Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis

BACKGROUND: Whether the histologic subtype (type 1 and type 2) of papillary renal cell carcinoma (pRCC) is a tool to predict the prognosis is of great debate. This study is aimed to evaluate the prognostic significance of histologic subtype in patients with pRCC after surgery through a systematic re...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Shengwei, Zhu, Weijie, Li, Xinfei, Yu, Yanfei, Yang, Kunlin, Zhang, Lei, Mi, Yue, Li, Xuesong, Zhou, Liqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421816/
https://www.ncbi.nlm.nih.gov/pubmed/34532250
http://dx.doi.org/10.21037/tau-21-329
_version_ 1783749166689681408
author Xiong, Shengwei
Zhu, Weijie
Li, Xinfei
Yu, Yanfei
Yang, Kunlin
Zhang, Lei
Mi, Yue
Li, Xuesong
Zhou, Liqun
author_facet Xiong, Shengwei
Zhu, Weijie
Li, Xinfei
Yu, Yanfei
Yang, Kunlin
Zhang, Lei
Mi, Yue
Li, Xuesong
Zhou, Liqun
author_sort Xiong, Shengwei
collection PubMed
description BACKGROUND: Whether the histologic subtype (type 1 and type 2) of papillary renal cell carcinoma (pRCC) is a tool to predict the prognosis is of great debate. This study is aimed to evaluate the prognostic significance of histologic subtype in patients with pRCC after surgery through a systematic review and meta-analysis. METHODS: We searched PubMed, the Web of Science, Cochrane library and EMBASE databases to identify studies published until January 20, 2021 according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Studies were deemed eligible if they compared the overall survival (OS), cancer specific survival (CSS), recurrence-free survival (RFS) or disease-free survival (DFS) between patients with type 1 or type 2 pRCC. And the corresponding hazard ratios (HRs) and 95% conference intervals (CIs) were collected for meta-analysis and further subgroup analysis. RESULTS: Overall 22 studies with a total of 4,494 patients were considered eligible and included for the systematic review and meta-analysis. The pooled results showed that type 2 pRCC was associated with a worse OS (pooled HR 1.61, 95% CI: 1.10–2.36, P=0.02) and CSS (pooled HR 1.59, 95% CI: 1.00–2.51, P=0.05). However, the subgroup analysis yielded the same result as the initial analysis only when the HRs were extracted from univariate analysis. In studies with multivariate analysis, type 2 pRCC was not statistically associated with a worse OS (pooled HR 1.22, 95% CI: 0.97–1.53, P=0.27), CSS (pooled HR 1.16, 95% CI: 0.67–2.00, P=0.60), and DFS (pooled HR 1.33, 95% CI: 0.93–1.91, P=0.12) compared to type 1 pRCC. DISCUSSION: Histologic subtype is not an independent prognostic factor for patients with pRCC, although the result needs to be taken with caution. And studies with retrospective study design, larger sample size and longer follow-up period are required to verify these results.
format Online
Article
Text
id pubmed-8421816
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-84218162021-09-15 Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis Xiong, Shengwei Zhu, Weijie Li, Xinfei Yu, Yanfei Yang, Kunlin Zhang, Lei Mi, Yue Li, Xuesong Zhou, Liqun Transl Androl Urol Original Article BACKGROUND: Whether the histologic subtype (type 1 and type 2) of papillary renal cell carcinoma (pRCC) is a tool to predict the prognosis is of great debate. This study is aimed to evaluate the prognostic significance of histologic subtype in patients with pRCC after surgery through a systematic review and meta-analysis. METHODS: We searched PubMed, the Web of Science, Cochrane library and EMBASE databases to identify studies published until January 20, 2021 according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Studies were deemed eligible if they compared the overall survival (OS), cancer specific survival (CSS), recurrence-free survival (RFS) or disease-free survival (DFS) between patients with type 1 or type 2 pRCC. And the corresponding hazard ratios (HRs) and 95% conference intervals (CIs) were collected for meta-analysis and further subgroup analysis. RESULTS: Overall 22 studies with a total of 4,494 patients were considered eligible and included for the systematic review and meta-analysis. The pooled results showed that type 2 pRCC was associated with a worse OS (pooled HR 1.61, 95% CI: 1.10–2.36, P=0.02) and CSS (pooled HR 1.59, 95% CI: 1.00–2.51, P=0.05). However, the subgroup analysis yielded the same result as the initial analysis only when the HRs were extracted from univariate analysis. In studies with multivariate analysis, type 2 pRCC was not statistically associated with a worse OS (pooled HR 1.22, 95% CI: 0.97–1.53, P=0.27), CSS (pooled HR 1.16, 95% CI: 0.67–2.00, P=0.60), and DFS (pooled HR 1.33, 95% CI: 0.93–1.91, P=0.12) compared to type 1 pRCC. DISCUSSION: Histologic subtype is not an independent prognostic factor for patients with pRCC, although the result needs to be taken with caution. And studies with retrospective study design, larger sample size and longer follow-up period are required to verify these results. AME Publishing Company 2021-08 /pmc/articles/PMC8421816/ /pubmed/34532250 http://dx.doi.org/10.21037/tau-21-329 Text en 2021 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Xiong, Shengwei
Zhu, Weijie
Li, Xinfei
Yu, Yanfei
Yang, Kunlin
Zhang, Lei
Mi, Yue
Li, Xuesong
Zhou, Liqun
Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis
title Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis
title_full Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis
title_fullStr Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis
title_full_unstemmed Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis
title_short Whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis
title_sort whether histologic subtyping affect the oncological outcomes of patients with papillary renal cell carcinoma: evidence from a systematic review and meta-analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421816/
https://www.ncbi.nlm.nih.gov/pubmed/34532250
http://dx.doi.org/10.21037/tau-21-329
work_keys_str_mv AT xiongshengwei whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis
AT zhuweijie whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis
AT lixinfei whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis
AT yuyanfei whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis
AT yangkunlin whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis
AT zhanglei whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis
AT miyue whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis
AT lixuesong whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis
AT zhouliqun whetherhistologicsubtypingaffecttheoncologicaloutcomesofpatientswithpapillaryrenalcellcarcinomaevidencefromasystematicreviewandmetaanalysis